Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development

NEXT STORY
Rapid Medical Diagnostic Kits Market Value Predicted To Reach US$ 24.6 Billion By 2027: Acumen Research And Consulting
PREV STORY
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of NLA101 in Patients with AML

SEATTLE, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a clinical stage ...

author_avatar
NASDAQ Market News

Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))

author_avatar
NASDAQ Market News

EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS)

author_avatar
NASDAQ Market News